Disease-A-Month
Volume 49, Issue 1 , Pages 22-38 , January 2003

Inhibitor treatment: State of the art

References 

  1. Baudo F, Redaelli R, Caimi TM, et al.  The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res. 2000;99:21–24
  2. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis. 1996;26(suppl 1):135–138
  3. Chuansumrit A, Isarangkura P, Angchaisuksiri P, et al.  Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia. 2000;6:61–65
  4. Cooper HA, Jones CP, Campion E, et al.  Successful use of high dose rFVIIa in a high titre inhibitor patient with haemophilia B during major orthopaedic manipulations and rehabilitation to release fixed flexion contractions of both knees. Haemophilia. 2000;6:297–298 (abstr 45)
  5. d'Oiron R, Ménart C, Trzeciak MC, et al.  Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83:644–647
  6. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis. 1991;21:1–4
  7. Grossmann RE, Geisen U, Schwender S, et al.  Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrands disease and alloantibodies against von Willebrand factor. Thromb Haemost. 2000;83:633–634
  8. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev. 1993;7:78–83
  9. Hedner U, Kristensen H, Berntorp E, et al.  Pharmacokinetics of rFVIIa in children. Haemophilia. 1998;4:355
  10. Jiménez-Yuste V, Villar A, Foncillas MA, et al.  Are higher doses needed of recombinant activated factor VII in haemophiliac paediatric patients with inhibitor?. Haemophilia. 2000;6(abstr):298
  11. Jiménez-Yuste V, Villar A, Morado M, et al.  Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Hemophilia. 2000;6:588–590
  12. Kenet G, Lubetsky A, Gitel S, et al.  Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII. Blood Coag Fibrinol. 2000;11:S35–S38
  13. Kenet G, Lubetzky A, Luboshitz J, et al.  Treatment of inhibitor patients with rFVIIa: Continuous infusion protocols as compared to a single, large, dose. Haemophilia. 2000;76:297; (abstr 44)
  14. Key NS, Aledort LM, Beardsley D, et al.  Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912–918
  15. Lindley CM, Sawyer WT, Macik BG, et al.  Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638–648
  16. Lorenzo JI, Montoro JM, Aznar JA. Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. Haemophilia. 1999;5:135–138
  17. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol. 1998;63:7–10
  18. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: Management. Semin Thromb Hemost. 2000;26:179–188
  19. Lusher JM, Ingerslev J, Roberts HR, et al.  Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinol. 1998;9:119–128
  20. Lusher JM, Roberts HR, Davignon G, et al.  A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. RFVIIa Study Group. Haemophilia. 1998;4:790–798
  21. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, et al.  Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med. 1998;53:249–255
  22. McPherson J, Sutcharitchan P, Lloyd J, et al.  Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region. Blood Coagul Fibrinol. 2000;11(suppl 1):S31–S34
  23. Ménart C, Cognet V, Petit PY, et al.  Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of NovoSeven. Blood Coagul Fibrinol. 1998;9:289–290
  24. Montoro JB, Altisent C, Pico M, et al.  Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia. 1998;4:762–765
  25. Rocino A, Miraglia E, Ziello L, et al.  Successful continuous infusion (CI) rFVIIa treatment during surgery in two high responding inhibitor patients with hemophilia A. Haemophilia. 1998;4:350; (abstr)
  26. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol. 1999;104:22–26
  27. Santagostino E, Rocino A, Gringeri A, et al.  Continuous infusion of recombinant activated factor VIIa (rFVIIa) for treatment of high titre inhibitor patients: The Italian experience. Haemophilia. 2000;6:279; (abstr 43)
  28. Saxon BR, Jory CB. Effective prophylaxis with daily rFVIIa (NovoSeven) in a child with high titre inhibitors and a target joint. Haemophilia. 2000;6:299; (abstr 49)
  29. Scaraggi FA, De Mitrio V, Marino R, et al.  Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: Advantages of administration by continuous infusion over bolus intermittent injections. Blood Coagul Fibrinol. 1999;10:33–38
  30. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia. 1998;4:564–567
  31. Schulman S, Bech Jensen M, Varon D, et al.  Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996;75:432–436
  32. Schulman S, d'Oiron R, Martinowitz U, et al.  Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinol. 1998;9(suppl 1):S97–S101
  33. Schulman S, rFVIIa-CI Group . Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness. Semin Thromb Hemost. 2000;26:421–424
  34. Smith MP, Ludlam CA, Collins PW, et al.  Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/mL is associated with an increased incidence of bleeding. Thromb Haemost. 2001;86:949–953
  35. Stieltjes N, Ounnoughene N, Vassilieff D, et al.  Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Haemost. 1997;50(suppl, abstr):PS-202
  36. Tagariello G, de Biasi E, Gajo GB, et al.  Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: Experience of two cases. Haemophilia. 2000;6:581–583
  37. Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery. Eur J Haematol. 1998;63(suppl):15–17

PII: S0011-5029(03)90012-5

doi: 10.1016/S0011-5029(03)90012-5

Disease-A-Month
Volume 49, Issue 1 , Pages 22-38 , January 2003

Article Tools

* Image Usage & Resolution